Boltz, a Massachusetts PBC spun out of MIT CSAIL research, launched Boltz Lab and open-source biomolecular AI models to accelerate structural prediction and therapeutic design. The company opened with a $28 million seed round led by Amplify, a16z, and Zetta to scale its open-model infrastructure for protein complex prediction, binding affinity and drug design agents. Boltz positions itself as tool-builder rather than a traditional therapeutics sponsor: its platform is designed to let bench scientists move from hypothesis to molecule without building proprietary ML stacks. Founders argued that open, widely adopted models will democratize early-stage discovery and shorten timelines for small biotechs and academic groups. Investors cited in the round signaled strong demand for AI-native discovery infrastructure; wider adoption will hinge on model validation, reproducibility, and integration with experimental pipelines.